ClinicaliQ Trial Snapshot
- AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Recruiting • Phase III • Diabetes / Metabolic • NCT07503210.
- AMAZE 12 Summary.
- Trial testing whether weekly injections of NNC0487-0111 help people maintain weight loss compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance. Conditions: Obesity Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111) Lead Sponsor: Novo Nordisk A/S Planned Enrollment: 600 participants